Seres Therapeutics is a late-clinical stage biotechnology company working to shift the treatment paradigm for a wide range of diseases by uncovering and enhancing the function of the human microbiome. Learn more: https://www.serestherapeutics.com/
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| 08.12.2025 | CARB-X | carb-x.org |
Mentions in press and media 15
| Date | Title | Description |
| 16.01.2025 | Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale | CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Comp... |
| 16.01.2025 | Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale | CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Comp... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 06.06.2024 | Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 | Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of ... |
| 30.11.2022 | FDA approves first fecal microbiome drug, setting stage for others | The Food and Drug Administration approved the first therapy using bacteria from stool samples to treat a bowel disorder on Wednesday, paving the way for several similar treatments in development. The drug, called Rebyota, is given as a one-... |
| 10.11.2021 | Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a... | Press Release | Nov 10. 2021 07:07 GMT SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint ven... |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!” If you spot someone wearing a tee shirt with that saying, there is some chance they work at a microbiome startup. If they don’t, it’s probably worth looking into. The human microbiome is a... |
| 12.06.2017 | Seres grabs $20M on PhIII microbiome launch | Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed a mid-stage study. The biotech says that it has learned from its setback and has now start... |
| 12.06.2017 | Seres grabs $20M on PhIII microbiome launch; Gilead submits NDA; Alkermes begins Phase IIIb study | → Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed a mid-stage study. The biotech says that it has learned from its setback and has now star... |
| 12.06.2017 | Seres initiates industry-first pivotal microbiome trial | Seres has long been a leader in the high-buzz microbiome field. In June 2015, it executed the industry’s first-ever initial public offering (IPO), raising an impressive $134 million. It also claimed the ticker symbol MCRB. But it’s not all ... |
Show more